Abstract
Aim
Clinical symptoms are the most important factors used by physicians to evaluate the severity and extent of ulcerative colitis (UC). In this context, colonoscopy is also a useful diagnostic tool. We have recently developed an endoscopic activity index (EAI) to assess the severity of UC. Here, we assess the correlations among the EAI, other endoscopic indices, and clinical scores. The usefulness of the EAI for choosing treatment options, such as intravenous corticosteroid or cyclosporine A (CsA), in severe UC patients was also evaluated.
Methods
Clinical symptoms and endoscopic finding were evaluated in 396 patients with UC (454 colonoscopies). The EAI was scored using the following six items: ulcer size, ulcer depth, redness, bleeding, edema, and mucus exudates. The patients were also scored using Matts’ grade, Rachmilewitz’s endoscopic index, and the Lichtiger index.
Results
Our results showed that (1) the EAI scores were closely correlated with those of the Lichtiger index, Matts’ grade, and Rachmilewitz’s endoscopic index; (2) the EAI scores significantly decreased in patients who responded to treatment, while Matts’ grade did not change in some responders treated with intravenous CsA and steroid; (3) patients with a higher EAI (14–16) tended to be refractory to corticosteroid therapy (responders 19%) compared to CsA (77%), while steroid treatment was effective in 58% of patients with EAI scores of 11–13.
Conclusions
The EAI is equivalent to other endoscopic indices and relatively more useful in choosing a treatment for patients with severe UC.
Similar content being viewed by others
References
Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J. 1955;2:104–8.
Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J. 1962;2:441–3.
Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.
D’Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, et al. Intravenous cyclosporin versus intravenous glucocorticosteroids as a single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001;120:1323–9.
Svavoni F, Bonassi U, Bagnolo F. Effectiveness of cyclosporine in the treatment of refractory ulcerative colitis. Gastroenterology. 1998;114:A1096.
Van Assche G, D’Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized double-blind comparison of 4 mg/kg/day versus 2 mg/kg/day intravenous cyclosporin in severe ulcerative colitis. Gastroenterology. 2003;125:1025–31.
Moskovitz D, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, et al. Incidence of colectomy during long term follow up after cyclosporin-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760–5.
Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–11.
Van Assche G, Vermeire S, Rutgeerts P. Treatment of severe steroid refractory ulcerative colitis. World J Gastroenterol. 2008;14:5508–11.
Rachmilwitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J. 1989;298:82–6.
Matts SGF. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med. 1961;30:393–407.
Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, et al. Granulocytopheresis is useful as an alterative therapy for steroid refractory and dependent ulcerative colitis. Inflamm Bowel Dis. 2004;10:251–7.
D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–86.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987;317:1625–9.
Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894–8.
Ando T, Nishio Y, Watanabe O, Takahashi H, Maeda O, Ishiguro K, et al. Value of colonoscopy for prediction of prognosis in patients with ulcerative colitis. World J Gastroenterol. 2008;14:2133–8.
Cacheux W, Seksik P, Lemann M, Marteau P, Nion-Larmurier I, Afchain P, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2008;103:637–42.
Acknowledgments
The authors would like to express thanks to Dr. Luba Wolchuk for kindly checking the English of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
M. Naganuma and H. Ichikawa contributed equally to this study.
Rights and permissions
About this article
Cite this article
Naganuma, M., Ichikawa, H., Inoue, N. et al. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol 45, 936–943 (2010). https://doi.org/10.1007/s00535-010-0244-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-010-0244-2